LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

Status Recruiting

Clinical Trial Summary

This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment.

Clinical Trial Description

This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved LY3214996 as a treatment for any disease. LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow. In this research study, the investigators are testing to see if LY3214996 is a safe treatment for AML that has returned or not responded to standard treatment. Several doses of the study drug will be explored in this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04081259
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact	Rahul Vedula, MD
Phone	617) 632-5435
Email	rahul_vedula@dfci.harvard.edu
Status	Recruiting
Phase	Phase 1
Start date	July 15, 2020
Completion date	April 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05400122` - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Phase 1
Recruiting	`NCT04460235` - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma	Phase 4
Completed	`NCT03678493` - A Study of FMT in Patients With AML Allo HSCT in Recipients	Phase 2
Completed	`NCT04022785` - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Phase 1
Recruiting	`NCT05424562` - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Terminated	`NCT03224819` - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)	Early Phase 1
Completed	`NCT03197714` - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia	Phase 1
Active, not recruiting	`NCT04070768` - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113	Phase 1
Active, not recruiting	`NCT03844048` - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial	Phase 3
Active, not recruiting	`NCT04107727` - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)	Phase 2
Recruiting	`NCT04920500` - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients	N/A
Recruiting	`NCT04385290` - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)	Phase 1/Phase 2
Recruiting	`NCT03897127` - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics	Phase 3
Active, not recruiting	`NCT04021368` - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome	Phase 1
Recruiting	`NCT03665480` - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML	Phase 2/Phase 3
Completed	`NCT02485535` - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant	Phase 1
Enrolling by invitation	`NCT04093570` - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers	Phase 2
Recruiting	`NCT04069208` - IA14 Induction in Young Acute Myeloid Leukemia	Phase 2
Recruiting	`NCT05744739` - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)	Phase 1
Recruiting	`NCT04969601` - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings	Phase 1/Phase 2